• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards

    The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards

  2. Meda and Valeant Terminate Joint Ventures

    Meda and Valeant Terminate Joint Ventures

  3. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  4. How to Tell if Your Fund Invests With Buffett

    Fund portfolio and Berkshire Hathaway shareholder data show which funds hold significant chunks of the company's stock.

  5. Benchmarks? What Benchmarks?

    Try this screen for core funds that take the road less travelled.

  6. Three Flavors of Focused Funds

    To say a manager is concentrating bets doesn't tell the whole story.

  7. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

  8. Education Fails = Economy Fails

    Valeant Pharmaceuticals VRX announced on Tuesday that its hepatitis C drug candidate Viramidine missed the efficacy endpoint in the second arm of its Phase III clinical trials. We'd previously placed $3 per share of value on this compound's potential, and we plan on reducing our fair value estimate ...

  9. Five Years Later: Fund Managers and Cash Stakes

    They provide cushions in downturns but don't come for free.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.